SynGenix develops new pain candidate

Published: 1-Jan-2003
Sustainability


SynGenix, based in Cambridge in the UK, has developed SGX 355, for long acting relief of neuropathic pain using its proprietary Controlled Kinetics technology.

Neuropathic pain can be associated with a diverse variety of conditions including diabetic neuropathy, amputation, multiple sclerosis and back pain. It is poorly treated by existing medication and has been a major target of pharmaceutical research.

SynGenix's Controlled Kinetics technology has been developed with the derivative of a known medication which is expected to result in significantly improved treatment for neuropathic pain.

'SynGenix's delivery systems are providing platforms for a new generation of drugs for the treatment of pain and neurological disease,' said Tom Saylor, ceo of SynGenix. 'SGX 355 for neuropathic pain is the first of a range of products built around Controlled Kinetics technology, which can offer greatly improved therapeutic benefits from existing drugs.'

The technology utilises advanced drug design chemistry to improve the physical characteristics of drugs and provide drug release systemically. For example, drugs with poor solubility can be formulated for significantly improved bioavailability.

SynGenix is building a portfolio of drugs to treat conditions of the nervous system based upon enhancement of existing medicines through targeting and modification of physical properties.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
  3. Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
  4. Five API manufacturing trends you need to know in 2025 How technology, sustainability and innovation are redefining pharmaceutical production
  5. GEA raises guidance following strong H1 performance Revised forecast reflects improved margins, robust order intake and efficiency gains

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Manufacturing

Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS

The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Sustainability

Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress

This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
Sustainability

Piramal Pharma publishes FY2025 sustainability report, outlining performance and decarbonization glidepath

Piramal Pharma Limited has released its fourth annual Sustainability Report for the financial year 2025, under the theme ‘Innovating Responsibly. Growing Sustainably.’
Sustainability

LOCTITE to showcase next generation of healthcare adhesive innovations

New biocompatible adhesives aim to improve safety, performance, and sustainability
Sustainability

IMCD receives upgraded ESG ratings from ISS ESG and Sustainalytics

Improvements reflect continued progress on emissions, transparency and ESG risk management
Subscribe now